APPLICATIONS AND SYNTHESIS OF NANOPARTICLES IN MEDICINE
Transcript of APPLICATIONS AND SYNTHESIS OF NANOPARTICLES IN MEDICINE
www.wjpr.net Vol 5, Issue 7, 2016.
365
Sarkar World Journal of Pharmaceutical Research
APPLICATIONS AND SYNTHESIS OF NANOPARTICLES IN
MEDICINE
Dr. Leena H. Sarkar
Department of Chemistry, J.V.M’s Degree College, Airoli, Navi Mumbai 400 708, India.
ABSTRACT
Nanoparticles are materials with dimensions of the nanoscale i.e.,
under 100 nm in size. Recently researchers have developed interest in
synthesis and applications of nanotechnology. It is considered as most
active area of research and advancements have been made in the field
of medicine, clinical applications, magnetic resonance imaging and
drug delivery systems. However, in some cases nanoparticles also
bring with them unique challenges to our society and environment, due
to their toxic nature. This review aims to highlight the major
contributions of nanoparticles to modern medicine and also discuss the
effects of nanoparticles on environment and society.
KEYWORDS: nanoparticles, contrast agents, drug delivery, tumors, quantum dots, cancer,
toxicity.
INTRODUCTION
Nanoparticles are particles between 1 and 100 nanometers in size.[1]
They are also referred as
“zero-dimensional” nanomaterials. In nanotechnology, a particle is defined as a small object
that behaves as a whole unit with respect to its transport and properties. Particles are further
classified according to diameter.[2]
Nanoparticles show unique properties compared to the
bulk metals therefore a lot of research work has been reported for the synthesis and
applications of metal nanoparticles.[3]
Nanoparticles have a number of novel optical, electronic, magnetic, structural properties,
chemical reactivity, energy absorption, and biological mobility compared with the same
materials at bulk volume by virtue of their size, making them attractive.
There are two main approaches for the synthesis of nanoparticles: top-down and bottom-up.
In top-down approach the material size is reduced from large to nanoscale, whereas in the
World Journal of Pharmaceutical Research SJIF Impact Factor 6.805
Volume 5, Issue 7, 365-379. Review Article ISSN 2277– 7105
*Corresponding Author
Dr. Leena H. Sarkar
Department of Chemistry,
J.V.M’s Degree College,
Airoli, Navi Mumbai 400
708, India.
Article Received on
24 April 2016,
Revised on 15 May 2016,
Accepted on 03 June 2016
DOI: 10.20959/wjpr20167-6467
www.wjpr.net Vol 5, Issue 7, 2016.
366
Sarkar World Journal of Pharmaceutical Research
bottom-up approach nanomaterials are synthesised by starting from the atomic level.[4,5]
The
top-down approach often uses the traditional methods where externally controlled tools are
used to cut, mill, and shape materials into the desired shape and order. Bottom-up approach
uses the chemical properties of single molecules to (a) self-organize or self-assemble into
some useful conformation, or (b) rely on positional assembly. The biggest problem with top
down approach is that it introduces internal stress, contaminations, surface defects leading to
imperfection of structure and crystallographic damage. These imperfections lead to extra
challenges in the fabrication. But this approach leads to the bulk production of nano
materials. Regardless of the defects produced by top down approach, they continue to play an
important role in the synthesis of nano structures. Though the bottom up approach is an old
concept observed in nature and has been used in industries for a long time. For example,
production of salt in chemical industry. Bottom up approach gives nano structures with less
defects and more homogeneous chemical composition.
These materials can be synthesized by several methods which include solid-phase, liquid-
phase and gas-phase processes. The solid-phase techniques include mechanical ball
milling[6,7]
and mechano chemical[7]
, the liquid-phase techniques which include laser
ablation[8,9]
, exploding wire[10]
, solution reduction[11]
, and decomposition process[12,13]
,
whereas the gas-phase processes include gas evaporation[14,15]
, exploding wire[16,17]
, and laser
ablation process.[18]
There are large number of applications of nanoparticles in medicine. This article reviews
synthesis, the role of nanoparticles in medicine, medical imaging and drug/gene delivery.
Also the effect of nanoparticles on environment has been discussed.
ROLE OF NANOPARTICLES (NPs) IN MAGNETIC RESONANCE IMAGING
(MRI)
Cancer is a disease for which mortality rate is very high. Treatment methods include surgery,
chemotherapy and radiation therapy. However, the results of the treatment are not positive in
many cases. The reasons behind this being ineffective early diagnosis, insufficient drug
concentrations reaching the tumour cells, adverse effects of drugs. Thus, the important issues
in improving treatment regimens are (i) development of advanced imaging technologies for
early diagnosis and (ii) utilization of targeting moieties to specifically and efficiently deliver
drugs to tumour tissues.
www.wjpr.net Vol 5, Issue 7, 2016.
367
Sarkar World Journal of Pharmaceutical Research
Harisinghani et al[19]
used SPIO nanoparticles to detect small metastases in the lymph node in
human patients with prostate cancer which would not be detected by conventional MRI.
SPIO nanoparticles allow the visualization of metastases that cannot be clearly observed by
conventional MRI. The significance of this work is that patients with localized disease have
the option of early treatment by surgery without being restricted to radiation therapy, the
primary treatment for advanced-stage patients.
Huh et al[20]
described the use of SPIO nanoparticles to detect cancer in vivo using a mouse
xenograft model. SPIO nanoparticles were prepared by the thermal decomposition of iron
acetylacetonate and made water-soluble by binding with 2, 3-dimercaptosuccinic acid and
then conjugated to herceptin, a cancer-targeting antibody. When administered intravenously
to mice, a rapid change was observed in the T2-weighted MRI signal from the tumor located
in the thigh of the animals.
Recently researchers at Imperial College London[21]
, have designed a new self-assembling
nanoparticle that boosts the effectiveness and sensitivity of Magnetic Resonance Imaging
(MRI) scanning, targets tumours and helps doctors for earlier diagnosis of cancer.
The nanoparticle is coated with a special protein, which looks for specific signals given off
by tumours, and when it finds a tumour it begins to interact with the cancerous cells. This
interaction strips off the protein coating, causing the nanoparticle to self-assemble into a
much larger particle so that a more powerful signal is obtained and a clearer MRI image of
the tumour is visible. This would enable doctors for faster detection of cancer and patients to
receive effective treatment sooner.
ROLE OF NANOPARTICLES IN OPTICAL IMAGING
Conventional imaging of cells and tissue sections is performed by loading organic dyes into
the sample. Dyes such as fluorescein isocyanate (FITC) and rhodamine are often attached to
biomolecules that selectively bind to cells or cell components through ligand/receptor
interactions. Inadequate fluorescence intensity and photobleaching i.e. gradual decrease in
fluorescence intensity are observed in this mode.
Fluorescent nanoparticles (NPs), such as organic dye-doped NPs, quantum dots enable highly
sensitive optical imaging of cancer at cellular and animal level.
www.wjpr.net Vol 5, Issue 7, 2016.
368
Sarkar World Journal of Pharmaceutical Research
NPs, when conjugated with several functional molecules like targeting moieties and imaging
probes, provides new potentials for clinical therapies and diagnostics. NP-based drug-
delivery systems based on polyethyleneimine (PEI), liposomes, micelles and silica NPs help
in easy drug delivery and reduce drug side effects.[22]
The core of the nanoparticle employs a phenomenon called plasmonics. In plasmonics,
nanostructured metals such as gold and silver[23]
resonate in light and concentrate the
electromagnetic field near the surface. In this way, fluorescent dyes are enhanced, appearing
about tenfold brighter than their natural state when no metal is present. When the core is
etched, the enhancement goes away and the particle becomes dim.
Quantum dots (QDs) are made of inorganic semiconductor molecules. They emit strong
fluorescent light under ultraviolet (UV) illumination. The wavelength of the emitted
fluorescent light depends on particle size. When QDs are excited by giving energy of a
specific wavelength, in the form of a photon an electron jumps from the valence band to the
conduction band and leaves behind a “hole”. When the excitation ceases, electrons come
back to the valence band, by emitting energy in form of light. Larger QDs have more
electron-hole pairs and are therefore capable of absorbing and releasing more energy. The
wavelength of emitted light decreases as QD size increases as energy is inversely
proportional to wavelength. Hence QDs emit light that is far more intense as compared to
conventional organic dyes. This is a major advantage in 3-D tissue imaging where
photobleaching is a major concern.[24]
QDs made of CdTe and capped with CdSe are capable of light emission under near infrared
excitation. This helps to locate lymph nodes up to 1 cm below the skin without the need for
surgical incisions.[25]
Akerman et al showed that QDs can be targeted to specific organs within the body by coating
them with appropriate molecules.[26]
TARGETING OF TUMORS USING NANOPARTICLES
Most anti-cancer drugs cannot differentiate between cancerous and normal cells, leading to
systemic toxicity and adverse effects. The maximal allowable dose is limited due to severe
side effects of the drugs to be delivered in a living system, resulting in inadequate drug
www.wjpr.net Vol 5, Issue 7, 2016.
369
Sarkar World Journal of Pharmaceutical Research
concentrations reaching the tumour cells. NPs can deliver anti-cancer drugs to tumour sites
efficiently benefiting cancer patients.[27]
Gold nanoparticles are emerging as promising agents for cancer therapy and are being
investigated as drug carriers, photothermal agents. Tumour targeting can be achieved by
actively binding tumour-specific recognition molecules such as epidermal growth factor
(EGF), transferrin, folic acid or monoclonal antibodies to nanoparticles.[28,29,30]
Scientists at UC Santa Barbara[23]
have designed silver nanoparticles that are spherical in
shape and are encased in a shell coated with a peptide that enables it to target tumor cells.
The shell is etchable so those nanoparticles that don’t hit their target can be broken down and
eliminated.
UCSB’s Ruoslahti Research Laboratory has also developed a simple etching technique which
uses biocompatible chemicals to rapidly disassemble and remove the silver nanoparticles
outside living cells. This method leaves only the intact nanoparticles for imaging or
quantification, thus revealing which cells have been targeted and how much each cell
internalized. “The disassembly is an interesting concept for creating drugs that respond to a
certain stimulus. It also minimizes the off-target toxicity by breaking down the excess
nanoparticles so they can then be cleared through the kidneys.” Since the nanoparticle has a
core shell structure, by varying its exterior coating the efficiency of tumor targeting and
internalization can be compared. Switching out the surface agent enables the targeting of
different diseases.
NANOPARTICLES IN DRUG AND GENE DELIVERY
Nowadays in drug therapy, a drug is transported to the place of action by using controlled
drug delivery systems (DDS)[31]
as a result, its effectiveness can be increased and its
influence on vital tissues and undesirable side effects can be reduced. Also, more drug
accumulates at the target site and so lower doses of drugs are required.
A drug may be adsorbed or covalently attached to the nanocarriers surface or else it can be
encapsulated into it. Covalent linking has the advantage over other ways of attaching as it
enables to control the number of drug molecules connected to the nanocarrier, i.e., a precise
control of the amount of the drug will be delivered. Cell-specific targeting with nanocarriers
www.wjpr.net Vol 5, Issue 7, 2016.
370
Sarkar World Journal of Pharmaceutical Research
may be accomplished by using active or passive mechanisms. Nanocarriers used for medical
applications have to be biocompatible and nontoxic.
SLN (solid lipid nanoparticles), NLC (nanostructured lipid carriers) and LDC (lipid drug
conjugates) are types of carrier systems based on solid lipid matrix i.e., lipids solid at the
body temperature.[32]
They have been exploited for the dermal[33]
, peroral[34]
, parenteral[35]
,
ocular[36]
, pulmonary[37]
, and rectal application.
Polymeric nanoparticles (PNPs) are structures obtained from synthetic polymers, such as
poly-e-caprolactone[38]
, polyacrylamide[39]
and poly-acrylate[40]
, or natural polymers, e.g.,
albumin[41]
, gelatin.[42]
Based on in vivo behavior, PNPs may be classified as biodegradable,
i.e., poly(L-lactide) (PLA)[43]
, poly-glycolide (PGA).[44]
Nanocarriers composed of
biodegradable polymers undergo hydrolysis in the body, producing biodegradable metabolite
monomers, such as lactic acid and glycolic acid. Kumari et al.[45]
reported a minimal systemic
toxicity associated with using of PLGA poly(lactic-co-glycolic acid) for drug delivery or
biomaterial applications. These biodegradable polymeric nanocarriers used for drug delivery
are stable in blood, non-toxic, and non-thrombogenic. They are also non-immunogenic as
well as non-proinflammatory, and they neither activate neutrophils nor affect
reticuloendothelial system.[46]
Some nanomers have dendritic structure eg. glycogen, amylopectin, and proteoglycans.[47]
They consist of a core with at least two identical functional groups, dendrons and surface
active groups. Dendrimers cytotoxicity and use of dendrimers in medical applications,
biocompatibility and physicochemical properties of dendrimers are determined by surface
functional groups.[48]
For example, changing the surface amine groups into hydroxyl ones may result in lower
levels of cytotoxicity. The presence of several surface functional groups enables a
simultaneous interaction with a number of receptors increasing its biological activity. The
drug may either be encapsulated in the internal structure of dendrimers[49]
when drugs are
labile, toxic, or poorly Soluble or else it can be chemically attached or physically adsorbed on
dendrimers surface[50]
which helps to control quantity of drugs on dendrimers surface by
controlling the number of covalent bonds.[51]
www.wjpr.net Vol 5, Issue 7, 2016.
371
Sarkar World Journal of Pharmaceutical Research
The surface of dendrimers provides an excellent platform for an attachment of specific
ligands, which may include folic acid[51]
, antibodies[52]
, cyclic targeting peptides – arginine-
glycine-aspartic acid (RGD).[53]
Poly(amido amide) (PAMAM) is a dendrimer which is
frequently used in biomedical applications.
Carbon nanotubes (CNTs) and nanohorns (CNH) are used as nanocarriers. Biocompatibility
of these nanotubes can be increased by chemical modification of their surface.[54]
Such
modification can be implemented by covalent anchoring of PAMAM dendrimers[55]
,
amphiphilic diblock copolymers[56]
or PEG layers[57]
on CNTs surface. Due to their
mechanical strength, SWCNTs (Single Walled Carbon Nanotubes have been used to improve
properties of other carriers, e.g., polymeric or non-polymeric composites.[58]
Drug
immobilization in carbon nanocarriers can be done by - encapsulation of a drug in the carbon
nanotube[59]
, chemical adsorption on the surface or in the spaces between the nanotubes (by
electrostatic, hydrophobic, p-p interactions and hydrogen bonds)[60,61]
, and attachment of
active agents to functionalized carbon nanotubes (f-CNTs). Encapsulation has the advantage
over the two remaining methods as the drug is protected from degradation during its transport
to the cells and is released only in specific conditions.[62]
To prevent the unwanted release of
the drug, the open ends of CNTs are sealed with polypyrrole (PPy) films.[63]
CANCER
Nanoparticles are used for the treatment of various types of cancers. Paclitaxel is used for
treatment of various types of cancer (such as skin, ovarian, lung and oesophageal.[64,65,66]
This drug interferes with the functions of cancer cells by microtubule stabilization, resulting
in apoptosis.[67]
A major shortcoming of this approach is the side effects associated with
Cremophor®, including hypersensitivity reactions, necessitating the administration of steroids
and antihistamines as premedications [68]. Abraxane® is a different form of paclitaxel where
paclitaxel is embedded within nanoparticles of a natural polymer, albumin, using a high-
pressure emulsification process. This form eliminates the side effects of Cremophor®[69]
and
the albumin carrier improves transport of the drug from the bloodstream to the tumor site and
allows higher drug dosing compared with Taxol.®
If a large number of cancerous cells are removable, then they should be removed surgically,
but even after removing a bigger tumor, residual cancer cells can be left behind in the area.
These residual cells can grow into tumors, leaving the possibility of the cancer recurring.
Detecting single residual cancer cells is not easy, however a cluster as small as three cancer
www.wjpr.net Vol 5, Issue 7, 2016.
372
Sarkar World Journal of Pharmaceutical Research
cells can be detected using the gold nanoparticle method. This method then becomes a very
useful option for two reasons: 1) detecting residual cancer cells, indicating whether more
tissue needs to be removed and 2) using this method to obliterate residual cancer cells. The
researchers had success with both methods, resulting in no cancer reappearance in their trials.
Removing residual cancer cells with nanoparticles was deemed a new type of surgery by the
researchers. They called it “PNB nanosurgery” which stands for Plasmonic Nano Bubble
nanosurgery.[70]
NEURODEGENERATIVE DISEASES
Treatment for neurodegenerative diseases is a challenge due to difficulty in Drug delivery to
the central nervous system.[71]
Nanoparticles made from poly (hexadecyl cyanoacrylate) and
related compounds have been shown to facilitate drug transport across the blood–brain barrier
(BBB). Kreuter et al[72, 72a]
adsorbed dalargin (an analgesic) onto poly(butyl cyanoacrylate)
(PBCA) nanoparticles and demonstrated penetration across the BBB in rats. More recently,
Siegemund et al[73]
showed how PBCA nanoparticles loaded with thioflavins can target
fibrillar amyloid β in a murine model of Alzheimer’s disease.
HIV/AIDS
De Jaeghere et al[74]
investigated the delivery of an HIV-1 protease inhibitor, CGP 70726,
using pH-sensitive nanoparticles made from a copolymer of methacrylic acid and ethyl
acrylate. This copolymer is commercially available under the name Eudragit®
L100–55. The
HIV-1 Tat protein has recently emerged as a potential candidate for a prophylactic or
therapeutic vaccine against HIV-1/AIDS.[75]
Study is still going on for solutions for the
disease.
Besides this nanoparticles have also been effectively used in the treatment of ocular
diseases[76,77]
and respiratory disease.[78,79,80]
EFFECTS OF NANOPARTICLES ON ENVIRONMENT AND SOCIETY
With the development of nanotechnology, the effects of nanomaterials, on the environment
and public health has received considerable attention in recent years. On one hand,
nanotechnological innovations have helped to improve the health of people and at the same
time different kinds of risks are associated with different nanoparticles.
www.wjpr.net Vol 5, Issue 7, 2016.
373
Sarkar World Journal of Pharmaceutical Research
Air pollution affects human health. Nanoparticles can be present in inhaled particulate matter
and may get deposited in the lungs. They can move from the lungs to other organs such as the
brain, the liver and possibly the foetus in pregnant women. The effects of inhaled
nanoparticles in the body may include lung inflammation, heart problems and other health
problems.
Studies have been done and toxic effects of Quantum dots[81,82]
; metallic, polymeric and
liposomal nanoparticles[83,84,85,86]
have been explored.
CONCLUSION
Nanoparticles have been recently used in the field of medicine for medical imaging,
drug/gene delivery. Innovations are also associated with certain harmful effects on
environment and society. We have to overcome these challenges.
REFERENCES
1. ASTM International E 2456-06 Terminology for nanotechnology. West Conshohocken,
PA: ASTM International, 2006.
2. Module 3: Characteristics of Particles – Particle Size Categories. epa.gov.
3. 5- Sulekh Chandra, Avdhesh Kumar, Praveen Kumar Tomar., Thermal and spectral
studies. Spectrochimica Acta Part A, 2012; 92: 392–397.
4. Charinpanitkul, T., Faungnawakij, K., Tanthapanichakoon, W., Adv Powder Technol,
2008; 19: 443.
5. Parvez Iqbal, Jon A. Preece, Paula M. Mendes, Nanotechnology: The “Top-Down” and
“Bottom-Up” Approaches, Nanotechnology Published Online: 15 Mar. 2012,
DOI: 10.1002/9780470661345.smc195, Copyright © 2012 John Wiley & Sons.
6. Thakur Prasad Yadav, Ram Manohar Yadav, Dinesh Pratap Singh, Nanoscience and
Nanotechnology, 2012; 2: 22-48.
7. Boldyrev, V.V. & Tkacova, K., Journal of Materials Synthesis and Processing, 2000; 8:
121-132.
8. Pronko P. P., Zhang Z., VanRompay P. A., App. Surf. Sci., 2003; 208: 492-501.
9. Ullmann M., Friedlander S. K., Schmidt-Ott A. J., Nanopart. Res., 2002; 4: 499-509.
10. P Sen, Joyee Ghosh, Alqudami Abdullah, Prashant Kumar, Vanada, Proc. Indian Acad.
Sci. (Chem. Sci.), 2003; 115: 499–508.
11. Vemal Raja Manikam, Kuan Yew Cheong, Khairunisak Abdul Razak, Materials Science
and Engineering:B, 2011; 176: 187–203.
www.wjpr.net Vol 5, Issue 7, 2016.
374
Sarkar World Journal of Pharmaceutical Research
12. Heting Li, Mohammed J. Meziani, Fushen Lu, Christopher E. Bunker, Elena A. Guliants,
and Ya-Ping Sun, J. Phys. Chem. C, 2009; 113: 20539–20542.
13. N. A. Niaz, Ishaq Ahmad, S. Nasir, Z. Wazir, R. Hussain, N. R. Khalid, S. Tajammul
Hussain, Digest Journal of Nanomaterials and Biostructures, 2013; 8: 423–431.
14. Sun X. K., Xu J., Chen W. X., Wei W. D., Nanostruct. Mater, 1994; 4: 337-44.
15. Puszynski J. A., Proc. Int. Pyrotech. 29th, 2002; 191-202.
16. L Yap, Y S Lee, W H Tay, C S Wong, Proceedings of the International Workshop On
Plasma Computations & Applications (IWPCA2008) 60-64.
17. T. K. Sindhu, R. Sarathi, S. R. Chakravarthy, Bulletin of Materials Science, 2007; 30:
187-195.
18. Han M., Gong Y., Zhou J., Yin C., Song F., Muto M., Takiya T., Iwata Y., Phys. Lett.,
2002; 302: 182-189.
19. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult
lymphnode metastases in prostate cancer. N Engl J Med., 2003; 348: 2491–99.
20. Huh YM, Jun YW, Song HT, et al. In vivo magnetic resonance detection of cancer by
using multifunctional magnetic nanocrystals. J. Am. Chem. Soc., 2005; 127: 12387–91.
21. Source: Imperial College London Date: July 16, 2014
22. Sinha R., Kim G. J., Nie S. M., Shin D. M., Nanotechnology in cancer therapeutics:
bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther., 2006; 5: 1909–
1917. (doi:10.1158/1535-7163.MCT-06-0141)
23. Julie Cohen, Sunday, June 8, 2014; 10: 00, Santa Barbara, CA.
24. Michalet X, Pinaud FF, Bentolila LA, et al. Quantum dots for live cells, in vivo imaging,
and diagnostics. Science, 2005; 307: 538–44.
25. Kim S, Lim YT, Soltesz EG, et al. Near-infrared fluorescent type II quantum dots for
sentinel lymph node mapping. Nat Biotechnol, 2004; 22: 93–7.
26. Akerman ME, Chan WCW, Laakkonen P, et al. Nanocrystal targeting in vivo. Proc Natl
Acad Sci U S A., 2002; 99: 12617–21.
27. Byrne J. D., Betancourt T., Brannon-Peppas L., Active targeting schemes for nanoparticle
systems in cancer therapeutics. Adv. Drug Del. Rev., 2008; 60: 1615-1626.
(doi:10.1016/j.addr.2008.08.005)
28. Chithrani BD, Ghazani AA, Chan WC. Determining the size and shape dependence of
gold nanoparticle uptake into mammalian cells. Nano Lett., 2006; 6: 662–8.
www.wjpr.net Vol 5, Issue 7, 2016.
375
Sarkar World Journal of Pharmaceutical Research
29. El-Sayed IH, Huang X, El-Sayed MA. Surface plasmon resonance scattering and
absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics:
applications in oral cancer. Nano Lett., 2005; 5: 829–34.
30. Eghtedari M, Liopo AV, Copland JA, Oraevsky AA, Motamedi M. Engineering of
hetero-functional gold nanorods for the in vivo molecular targeting of breast cancer
cells.Nano Lett, 2009; 9: 287–91.
31. Nevozhay D, Kañska U, Budzyñska R, Boratyñski J: Current status of research on
conjugates and related drug delivery systems in the treatment of cancer and other diseases
(Polish). Postepy HigMed Dosw, 2007; 61: 350–360.
32. Wissing SA, Kayser O, Müller RH: Solid lipid nanoparticles for parenteral drug delivery.
Adv Drug Deliv Rev, 2004; 56: 1257–1272.
33. Abdel-Mottaleb MMA, Neumann D, Lamprecht A: Lipid nanocapsules for dermal
application: A comparative study of lipid-based versus polymer-based nanocarriers. Eur J
Pharm Biopharm, 2011; 79: 36–42.
34. Muchow M, Maincent P, Müller RH: Lipid nanoparticles with a solid matrix (SLN, NLC
LDC) for oral drug delivery. Drug Dev Ind Pharm, 2008; 34: 1394–1405.
35. Nayak AP, Tiyaboonchai W, Patankar S, Madhusudhan B, Souto EB: Curcuminoids-
loaded lipid nanoparticles: novel approach towards malaria treatment. Colloids Surf B
Biointerfaces, 2010; 81: 263–273.
36. Attama AA, Schicke BC, Paepenmüller T, Müller-Goymann CC: Solid lipid
nanodispersions containing mixed lipid core and a polar heterolipid: characterization. Eur
J Pharm Biopharm, 2007; 67: 48–57.
37. Liu J, Gong T, Fu H,Wang C,Wang X, Chen Q, Zhang Q, He Q, Zhang Z: Solid lipid
nanoparticles for pulmonary delivery of insulin, Int J Pharm, 2008; 356: 333–344.
38. Bilensoy E, Sarisozen C, Esendagl G, Dogan LA, Aktas Y, Sen M, Mangan AN:
Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of
Mitomycin C to bladder tumors. Int J Pharm, 2009; 371: 170–176.
39. Bai J, Li Y, Du J, Wang S, Zheng J, Yang O, Chen X: One-pot synthesis of
polyacrylamide-gold nanocomposite. Mater Chem Phys, 2007; 106: 412–415.
40. Turos E, Shim JY, Wang Y, Greenhalgh K, Reddy GS, Dickey S, Lim DV: Antibiotic-
conjugated polyacrylate nanoparticles: New opportunities for development of anti-MRSA
agents. Bioorg Med Chem Lett, 2007; 17: 53–56.
www.wjpr.net Vol 5, Issue 7, 2016.
376
Sarkar World Journal of Pharmaceutical Research
41. Martinem A, Iglesias I, Lozano R, Teijon JM, Blanco MD: Synthesis and characterization
of thiolated alginate-albumin nanoparticles stabilized by disulfide bonds. Evaluation as
drug delivery systems. Carbohydr Polym, 2011; 83: 1311–1321.
42. Saraog GK, Gupta P, Gupta UD, Jain NK, Agrawal GP: Gelatin nanocarriers as potential
vectors for effective management of tuberculosis. Int J Pharm, 2010; 385: 143–149.
43. Mainardes RM, Khalil NM, Gremião MPD: Intranasal delivery of zidovudine by PLA
and PLA–PEG blend nanoparticles. Int J Pharm, 2010; 395: 266–271.
44. Park J, Fong PM, Lu J, Russell KS, Booth KJ, Saltzman WM, Fahmy TM: PEGylated
PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine, 2009; 5:
410-418.
45. Kumari A, Yadav SK, Yadav SC: Biodegradable polymeric nanoparticles based drug
delivery systems. Colloids Surf B Biointerfaces, 2010; 75: 1–18.
46. des Rieux A, Fievez V, Garinot M, Schneider YJ, Préat V: Nanoparticles as potential oral
delivery systems of proteins and vaccines: a mechanistic approach. J Control Release,
2006; 116: 1–27.
47. Svenson S, Tomalia DA: Dendrimers in biomedical applications – reflections on the field.
Adv Drug Deliv Rev, 2005; 57: 2106–2129.
48. Caminade AM, Laurent R, Majoral JP: Characterization of dendrimers. Adv Drug Deliv
Rev, 2005; 57: 2130–2146.
49. D’Emanuele A, Attwood D: Dendrimer-drug interactions. Adv Drug Deliv Rev, 2005; 57:
2147–2162.
50. Menjoge AR, Kannan RM, Tomalia DA: Dendrimerbased drug and imaging conjugates:
design considerations for nanomedical applications. Drug Discov Today, 2010; 15: 171–
187.
51. Singh P, Gupta U, Asthana A, Jain NK: Folate and Folate-PEG-PAMAM dendrimers:
synthesis, characterization, and targeted anticancer drug delivery potential in tumor
bearing mice. Bioconjugate Chem, 2008; 19: 2239–2252.
52. Wängler C, Moldenhauer G, Eisenhut M, Haberkorn U, Mier W: Antibody-dendrimer
conjugates: the number, not the size of the dendrimers, determines the imunoreactivity.
Bioconjug Chem, 2008; 19: 813–820.
53. Waite CL, Roth ChM: PAMAM-RGD conjugates enhance siRNA delivery through a
multicellular spheroid model of malignant glioma. Bioconjug Chem, 2009; 20: 1908–
1916.
www.wjpr.net Vol 5, Issue 7, 2016.
377
Sarkar World Journal of Pharmaceutical Research
54. Foldvari M, Bagonluri M: Carbon nanotubes as functional excipients for nanomedicines:
I. Pharmaceutical properties. Nanomedicine, 2008; 4: 173–182.
55. Zhang B, Chen Q, Tang H, Xie Q, Ma M, Tan L, Zhang Y, Yao S: Characterization of
and biomolecule immobilization on the biocompatible multi-walled carbon nanotubes
generated by functionalization with polyamidoamine dendrimers. Colloids Surf B
Biointerfaces, 2010; 80: 18–25.
56. Di Crescenzo A, Velluto D, Hubbell JA, Fontana A: Biocompatible dispersions of carbon
nanotubes: a potential tool for intracellular transport of anticancer drugs. Nanoscale,
2011; 3: 925–928.
57. Bhirde AA, Patel S, Sousa AA, Patel V, Molinolo AA, Ji Y, Leapman RD et al.:
Distribution and clearance of PEG-single-walled carbon nanotube cancer drug delivery
vehicles in mice. Nanomedicine, 2010; 5: 1535–1546.
58. Shin US, Yoon IK, Lee GS, Jang WC, Knowles JC, Kim HW: Carbon nanotubes in
nanocomposites and hybrids with hydroxyapatite for bone replacements. J Tissue Eng,
2011. (doi:10.4061/2011/674287).
59. Arsawang U, Saengsawang O, Rungrotmongkol T, Sornmee P, Wittayanarakul K,
Remsungnen T, Hannongbua S: How do carbon nanotubes serve as carriers for
gemcitabine transport in a drug delivery system? J Mol Graph Model, 2011; 29: 591–596.
60. Chen Z, Pierre D, He H, Tan S, Pham-Huy C, Hong H,Huang J: Adsorption behavior of
epirubicin hydrochloride on carboxylated carbon nanotubes. Int J Pharm, 2011; 28: 405,
153–161.
61. Zhang D, Pan B, Wu M, Wang B, Zhang H, Peng H, Wu D, Ning P: Adsorption of
sulfamethoxazole on functionalized carbon nanotubes as affected by cations and anions.
Environ Pollut., 2011; 159: 2616–2621.
62. Perry JL, Martin CR, Stewart JD: Drug-delivery strategies by using template-synthesized
nanotubes. Chemistry, 2011; 17: 6296–6302.
63. Luo X, Matranga C, Tan S, Alba N, Cui XT: Carbon nanotube nanoreservior for
controlled release of anti-inflammatory dexamethasone. Biomaterials, 2011; 32: 6316–
6323.
64. Kikuchi A, Sakamoto H, Yamamoto T. Weekly carboplatin and paclitaxel is safe, active,
and well tolerated in recurrent ovarian cancer cases of Japanese women previously treated
with cisplatin containing multidrug chemotherapy. Int J Gynecol Cancer, 2005; 15: 45–9.
www.wjpr.net Vol 5, Issue 7, 2016.
378
Sarkar World Journal of Pharmaceutical Research
65. Chao Y, Li CP, Chao TY, et al. An open, multi-centre, phase II clinical trial to evaluate
the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced
gastric cancer. Br J Cancer, 2006; 95: 159–63.
66. Roof KS, Coen J, Lynch TJ, et al. Concurrent cisplatin, 5-FU, pacli-taxel, and radiation
therapy in patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol
Phys., 2006; 65: 1120–8.
67. Koziara JM, Whisman TR, Tseng MT, et al. In-vivo efficacy of novel paclitaxel
nanoparticles in paclitaxel-resistant human colorectal tumors. J Control Release, 2006;
112: 312–19.
68. Zhang JA, Anyarambhatla G, Ma L, et al. Development and characterization of a novel
Cremophor (R) EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm
Biopharm, 2005a; 59: 177–87.
69. Micha JP, Goldstein BH, Birk CL, et al. Abraxane in the treatment of ovarian cancer: The
absence of hypersensitivity reactions. Gynecol Oncol, 2006; 100: 437–8.
70. Meier, J. D., Oliver, D. A. & Varvares, M. A. Surgical margin determination in head and
neck oncology: current clinical practice. The results of an International American Head
and Neck Society Member Survey. Head Neck, 2005; 27: 952–958.
71. Garcia-Garcia E, Andrieux K, Gil S, et al. Colloidal carriers and blood-brain barrier
(BBB) translocation: A way to deliver drugs to the brain? Int J Pharm., 2005; 298: 274–
92.
72. Kreuter J, Ramge P, Petrov V, et al. Direct evidence that polysorbate-80-coated
poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms
requiring prior binding of drug to the nanoparticles. Pharm Res., 2003; 20: 409–16. a
http://www.ncbi.nlm.nih.gov/pmc/articles
73. Siegemund T, Paulke BR, Schmiedel H, et al. Thioflavins released from nanoparticles
target fibrillar amyloid beta in the hippocampus of APP/PS1 transgenic mice. Int J Dev
Neurosci, 2006; 24: 195–201.
74. De Jaeghere F, Allemann E, Kubel F, et al. Oral bioavailability of a poorly water soluble
HIV-1 protease inhibitor incorporated into pH-sensitive particles: effect of the particle
size and nutritional state. J Control Release, 2000; 68: 291–8.
75. Caputo A, Gavioli R, Ensoli B. Recent advances in the development of HIV-1 Tat-based
Vaccines. Curr HIV Res, 2004; 2: 357–76.
76. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv
Rev., 2005; 57: 1595–639.
www.wjpr.net Vol 5, Issue 7, 2016.
379
Sarkar World Journal of Pharmaceutical Research
77. Pignatello R, Bucolo C, Ferrara P, et al. Eudragit RS100 (R) nano-suspensions for the
ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci., 2002a: 16: 53–61.
78. John AE, Lukacs NW, Berlin AA, et al. Discovery of a potent nanoparticle P-selectin
antagonist with anti-inflammatory effects in allergic airway disease. FASEB J, 2003; 17:
2296–8.
79. Pison U, Welte T, Giersig M, et al. Nanomedicine for respiratory diseases. Eur J
Pharmacol, 2006; 533: 341–50.
80. Kumar M, Kong X, Behera A, et al. Chitosan IFN-γ-pDNA nanoparticle (CIN) therapy
for allergic asthma. Genet Vaccines Ther, 2003; 1: 3.
81. Derfus AM, Chan WCW, Bhatia SN. Probing the cytotoxicity of semiconductor quantum
dots. Nano Lett, 2004; 4: 11–18.
82. Ballou B, Lagerholm BC, Ernst LA, et al. Noninvasive imaging of quantum dots in
mice. Bioconjugate Chem, 2004; 15: 79–86.
83. Muldoon LL, Sandor M, Pinkston KE, et al. Imaging, distribution, and toxicity of
superparamagnetic iron oxide magnetic resonance nanoparticles in the rat brain and
intracerebral tumor. Neurosurgery, 2005; 57: 785–96.
84. Hainfeld JF, Slatkin DN, Focella TM, et al. Gold nanoparticles: a new X-ray contrast
agent. Br J Radiol, 2006; 79: 248–53.
85. Alonso MJ. Nanomedicines for overcoming biological barriers. Biomed
Pharmacother, 2004; 58: 168–72.
86. Owens DE, Peppas NA. Opsonization, biodistribution, and pharma-cokinetics of
polymeric nanoparticles. Int J Pharm, 2006; 307: 93–102.